Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice

Multiple myeloma (MM) is the most common cancer affecting the bone and bone marrow and remains incurable for most patients; novel therapies are therefore needed. Bortezomib (Btz) is an FDA-approved drug for the treatment of patients with MM. However, its severe side effects require a dose reduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hua, Xiao, Lifeng, Tao, Jianguo, Srinivasan, Venkat, Boyce, Brendan F., Ebetino, Frank H., Oyajobi, Babatunde O., Boeckman, Robert K., Xing, Lianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161102/
https://www.ncbi.nlm.nih.gov/pubmed/30201882
http://dx.doi.org/10.3390/pharmaceutics10030154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161102/
https://www.ncbi.nlm.nih.gov/pubmed/30201882
http://dx.doi.org/10.3390/pharmaceutics10030154

Ejemplares similares